Printer Friendly

Optilite Special Protein Analyser Launches in North America.

M2 PHARMA-September 2, 2015-Optilite Special Protein Analyser Launches in North America

(C)2015 M2 COMMUNICATIONS

- US-based protein diagnostics specialist Binding Site has launched its Optilite fully-automated special protein analyser in North America, the company said on Wednesday.

Optilite is the first dedicated benchtop special protein analyser on the market since the company launched its own SPAPLUS instrument in 2006, and is specifically designed for laboratory workflow optimization.

Data from laboratories running Optilite show 40% faster processing of complex protein assays compared to other special protein analyzers on the market, Binding Site said.

Optilite's continuous loading of samples, reagents, and consumables plus automatic re-dilution to end result enable labs to maximize test throughput while minimising hands-on time.

A menu of special protein assays, including Binding Site's Freelite test, is currently available with additional assays under development.

The Optilite system and current menu are FDA cleared and Health Canada registered.

With a compact benchtop design, Optilite is quick to install, easy to maintain, and is equipped with full LIS connectivity and automatic barcode recognition for full traceability.

Unique to Optilite is a robust antigen excess protection system with three detection methods, thereby ensuring accurate and reliable results.

Binding Site focuses on research, development, manufacture and distribution of innovative immunodiagnostic systems and assays for the global laboratory market.

By utilizing its specialized expertise in antibody specificity technology, Binding Site has developed a menu of special protein assays, including the Freelite test, the only FDA cleared and guideline-recommended serum free light chain assay on the market.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 2, 2015
Words:263
Previous Article:For US HHS Secretary Sebelius Named to Humacyte Board of Directors.
Next Article:Incyte enters into global license and collaboration agreement with Jiangsu Hengrui Medicine Co for SHR-1210.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters